Filing Flows › Keros Therapeutics (KROS) › R&D spending
Keros Therapeutics (KROS) R&D spending by quarter
Keros Therapeutics' R&D spending was $20.5M in Q3 2026 (third quarter 2026), +27% from Q1 2026. Over the last 5 quarters it ranged from $16.1M (Q1 2026) to $48.7M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $20.5M | +27% | — |
| Q1 2026 | $16.1M | -10% | -67% |
| Q4 2025 | $17.9M | -59% | — |
| Q2 2025 | $43.5M | -11% | — |
| Q1 2025 | $48.7M | — | — |
Q3 2026 at a glance
Keros Therapeutics, Q3 2026: revenue $40.0M (+183% year over year), operating margin 32.0%, net earnings $14.2M, operating cash flow $3.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Keros Therapeutics' R&D spending?
Keros Therapeutics' R&D spending was $20.5M in Q3 2026 (third quarter 2026), +27% from Q1 2026.
How has Keros Therapeutics' R&D spending changed?
Over the last 5 quarters it ranged from $16.1M (Q1 2026) to $48.7M (Q1 2025).